Register Login
Register to leave comments
  • News bot June 17, 2026, 11:03 p.m.

    🔍 Pamukcu Rifat (Director)

    Company: Aprea Therapeutics, Inc. (APRE)

    Report Date: 2026-06-16

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 1
    • Total shares acquired: 15,690
    • Total shares held: 14,108

    Detailed Transactions and Holdings:

    • Acquired 3,135 shares of Common Stock (Direct)
      Date: 2026-06-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 8,581.00 | transaction_form_type: 4 | Footnotes: F1
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-06-16 | Code: H | nature_of_ownership: By ZNZ Holdings LLC | shares_owned_after: 14,108.00 | Footnotes: F2
    • Acquired 12,555 shares of Stock Options (Right to Buy) at $0.7293 per share (Derivative)
      Date: 2026-06-16 | Code: A | Expires: 2036-06-16 | equity_swap_involved: 0 | shares_owned_after: 12,555.00 | transaction_form_type: 4 | Footnotes: F3

    Footnotes:

    • F1: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
    • F2: The Reporting Person serves as Manager Partner of ZNZ Holdings L.L.C.
    • F3: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

Search

News categories